U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16NO
Molecular Weight 166.2401
Optical Activity NONE
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of EDROPHONIUM

SMILES

CC[N+](C)(C)C1=CC=CC(O)=C1

InChI

InChIKey=VWLHWLSRQJQWRG-UHFFFAOYSA-O
InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity NONE

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Originator

Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

1985
Preventing
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

1985
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
84.2 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
56.6 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
110 min
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
110 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Advances in the diagnosis of neuromuscular junction disorders.
2005-08
Management of myasthenia gravis.
2005-05-14
Postinfectious myasthenia gravis: report of two children.
2005-05
Clinical utility of videofluorography with concomitant Tensilon administration in the diagnosis of bulbar myasthenia gravis.
2005-05
MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence.
2005-05
Does this patient have myasthenia gravis?
2005-04-20
Edrophonium-induced right ventricular outflow tract tachycardia.
2005-01
Respiratory failure as a first presentation of myasthenia gravis.
2004-12
Myasthenia gravis and pregnancy: clinical implications and neonatal outcome.
2004-11-16
Painful sweating.
2004-10-26
A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor.
2004-10
Evaluation of mechanisms of azinphos-methyl resistance in the codling moth Cydia pomonella (L.).
2004-10
Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience.
2004-09-11
Pupil-sparing, painless compression of the oculomotor nerve by expanding basilar artery aneurysm: a case of ocular pseudomyasthenia.
2004-09
Ocular myasthenia gravis.
2004-09
'Dropped head sign' in myasthenia gravis.
2004-09
Sensory testing of the esophagus.
2004-09
Immunological and electrophysiological investigations of severe ptosis after bone marrow transplantation.
2004-09
Anticholinesterase therapy for patients with ophthalmoplegia following snake bites: report of two cases.
2004-08
Does acetylcholinesterase inhibition affect catecholamine secretion by adrenomedullary cells?
2004-07
Persistent diplopia after retrobulbar anesthesia.
2004-06
Nitric oxide and cardiac muscarinic control in humans.
2004-05
Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
2004-04-13
[Response to thymectomy in patients with thymoma].
2004-03-12
[A case of transient left ventricular ballooning ("Takotsubo"-shaped cardiomyopathy) developed during plasmapheresis for treatment of myasthenic crisis].
2004-03
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.
2004-03
[Comparison between idiopathic achalasia and achalasia caused by Chagas' disease: a review on the publications about the subject].
2004-02-06
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports.
2004-02
Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy.
2004-01
Prevalence of esophageal disorders in patients with recurrent chest pain.
2004
Myasthenia gravis in childhood.
2004
Natural monomeric form of fetal bovine serum acetylcholinesterase lacks the C-terminal tetramerization domain.
2003-12-30
Ocular myasthenia gravis associated with euthyroid ophthalmopathy.
2003-12
Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.
2003-11
Interactions of edrophonium with neostigmine in the rat trachea.
2003-10
Antinociception of intrathecal cholinesterase inhibitors and cholinergic receptors in rats.
2003-10
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
2003-10
Cage amines as the stopper inhibitors of cholinesterases.
2003-09-01
Chiropractic care of a pediatric patient with myasthenia gravis.
2003-08-07
[Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody].
2003-08
Positive tensilon test and intracranial tumor: a case report.
2003-07
Clinical profile of myasthenia gravis in the Sultanate of Oman.
2003-07
Facile synthesis of [11C]edrophonium and its analogues as new potential PET imaging agents for heart acetylcholinesterase.
2003-05-19
Utility of ambulatory 24-hour esophageal pH and motility monitoring in noncardiac chest pain: report of 90 patients and review of the literature.
2003-05
Assessment of esophageal function in patients with myasthenia gravis.
2003-05
The edrophonium test.
2003-03
Esophageal manometry in patients with clinical symptoms mimicking esophageal origin: a hospital-based ten-year experience.
2003-01
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
2003
[Premonitory depression].
2003
Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much?
2001-09
Patents

Sample Use Guides

In Vivo Use Guide
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8 Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated. Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions. For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:13:23 GMT 2025
Edited
by admin
on Mon Mar 31 18:13:23 GMT 2025
Record UNII
70FP3JLY7N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EDROPHONIUM CATION
Preferred Name English
EDROPHONIUM
VANDF   WHO-DD  
Common Name English
BENZENAMINIUM, N-ETHYL-3-HYDROXY-N,N-DIMETHYL-
Systematic Name English
EDROPHONIUM [VANDF]
Common Name English
ETHYL(M-HYDROXYPHENYL)DIMETHYLAMMONIUM
Systematic Name English
EDROPHONIUM ION
Common Name English
Edrophonium [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
NDF-RT N0000175723
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
NDF-RT N0000000177
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
Code System Code Type Description
CHEBI
251408
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
SMS_ID
100000087722
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
RXCUI
1546421
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
ALTERNATIVE
CAS
312-48-1
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
PUBCHEM
3202
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
RXCUI
3752
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
LACTMED
Edrophonium
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
WIKIPEDIA
Edrophonium
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
MESH
D004491
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
FDA UNII
70FP3JLY7N
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
EVMPD
SUB01860MIG
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID4046943
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
DRUG BANK
DB01010
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
DRUG CENTRAL
988
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
DAILYMED
70FP3JLY7N
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
NCI_THESAURUS
C76137
Created by admin on Mon Mar 31 18:13:23 GMT 2025 , Edited by admin on Mon Mar 31 18:13:23 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY